Amanote Research
Register
Sign In
The Efficacy Versus Toxicity Profile of Combination Virotherapy and TLR Immunotherapy Highlights the Danger of Administering TLR Agonists to Oncolytic Virus-Treated Mice
Molecular Therapy
- United States
doi 10.1038/mt.2013.48
Full Text
Open PDF
Abstract
Available in
full text
Categories
Molecular Medicine
Molecular Biology
Pharmacology
Medicine
Genetics
Drug Discovery
Date
April 1, 2013
Authors
Unknown
Publisher
Elsevier BV
Related search
Synergistic Induction of Interferon Α Through TLR-3 and TLR-9 Agonists Stimulates Immune Responses Against Measles Virus in Neonatal Cotton Rats
Vaccine
Molecular Medicine
Public Health
Veterinary
Microbiology
Environmental
Immunology
Infectious Diseases
Occupational Health
Response of Human Periodontal Ligament Stem Cells to IFN-γ and TLR-agonists
Scientific Reports
Multidisciplinary
Microbial TLR Agonists and Humoral Immunopathogenesis in HIV Disease
Epidemiology: Open Access
Combination Therapy With Proteasome Inhibitors and TLR Agonists Enhances Tumour Cell Death and IL-1β Production
Cell Death and Disease
Molecular Neuroscience
Immunology
Cell Biology
Cancer Research
Cellular
Medicine
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Frontiers in Oncology
Cancer Research
Oncology
A Combination of TLR-4 Agonist and Saponin Adjuvants Increases Antibody Diversity and Protective Efficacy of a Recombinant West Nile Virus Antigen
npj Vaccines
Infectious Diseases
Immunology
Pharmacology
Oncolytic Virotherapy
Nature Biotechnology
Applied Microbiology
Biotechnology
Biomedical Engineering
Molecular Medicine
Bioengineering
TLR Signaling
Cell Death and Differentiation
Cell Biology
Molecular Biology
Delivery and Biosafety of Oncolytic Virotherapy
Frontiers in Oncology
Cancer Research
Oncology
